Ind-Swift Laboratories Past Earnings Performance
Past criteria checks 2/6
Ind-Swift Laboratories has been growing earnings at an average annual rate of 66.8%, while the Pharmaceuticals industry saw earnings growing at 11.8% annually. Revenues have been declining at an average rate of 2% per year. Ind-Swift Laboratories's return on equity is 19.6%, and it has net margins of 40.5%.
Key information
66.82%
Earnings growth rate
65.87%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.49% |
| Revenue growth rate | -2.05% |
| Return on equity | 19.62% |
| Net Margin | 40.55% |
| Last Earnings Update | 30 Jun 2025 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Ind-Swift Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 25 | 5,674 | 2,301 | 1,224 | 0 |
| 31 Mar 25 | 5,617 | 2,505 | 1,252 | 0 |
| 31 Dec 24 | 4,635 | 3,540 | 633 | 0 |
| 30 Sep 24 | 7,423 | 3,734 | 936 | 0 |
| 30 Jun 24 | 10,037 | 4,047 | 1,199 | 0 |
| 31 Mar 24 | 17,091 | 5,388 | 2,475 | 0 |
| 31 Dec 23 | 12,004 | 432 | 1,534 | 0 |
| 30 Sep 23 | 12,256 | 513 | 1,495 | 0 |
| 30 Jun 23 | 12,375 | 450 | 1,410 | 0 |
| 31 Mar 23 | 12,159 | 476 | 1,401 | 0 |
| 31 Dec 22 | 12,231 | 113 | 1,279 | 0 |
| 30 Sep 22 | 11,571 | -2 | 1,234 | 0 |
| 30 Jun 22 | 10,691 | -11 | 1,164 | 0 |
| 31 Mar 22 | 10,529 | -21 | 1,278 | 0 |
| 31 Dec 21 | 9,754 | 301 | 1,163 | 0 |
| 30 Sep 21 | 9,555 | 256 | 1,144 | 0 |
| 30 Jun 21 | 9,536 | 111 | 1,130 | 0 |
| 31 Mar 21 | 9,068 | -31 | 1,079 | 0 |
| 31 Dec 20 | 8,776 | 277 | 1,097 | 0 |
| 30 Sep 20 | 8,536 | 77 | 1,082 | 0 |
| 30 Jun 20 | 8,360 | -111 | 1,022 | 0 |
| 31 Mar 20 | 7,993 | -212 | 1,058 | 0 |
| 31 Dec 19 | 7,977 | -734 | 1,021 | 0 |
| 30 Sep 19 | 7,992 | -211 | 1,012 | 0 |
| 30 Jun 19 | 7,872 | -35 | 929 | 0 |
| 31 Mar 19 | 7,790 | 289 | 1,018 | 0 |
| 31 Mar 18 | 7,769 | 220 | 963 | 0 |
| 31 Mar 17 | 7,142 | -391 | 765 | 0 |
| 31 Mar 16 | 6,641 | -587 | 694 | 0 |
| 31 Mar 15 | 6,778 | -1,194 | 571 | 0 |
Quality Earnings: 532305 has a large one-off gain of ₹2.2B impacting its last 12 months of financial results to 30th June, 2025.
Growing Profit Margin: 532305's current net profit margins (40.5%) are higher than last year (40.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 532305 has become profitable over the past 5 years, growing earnings by 66.8% per year.
Accelerating Growth: 532305's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 532305 had negative earnings growth (-43.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (15.7%).
Return on Equity
High ROE: 532305's Return on Equity (19.6%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/06 12:40 |
| End of Day Share Price | 2025/10/06 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ind-Swift Laboratories Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hitesh Kuvelkar | First Global Stockbroking (P) Ltd. |